These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 16180993)
1. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993 [TBL] [Abstract][Full Text] [Related]
2. A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. Lee JC; Chang CF; Chi YH; Hwang DR; Hsu JT J Virol Methods; 2004 Mar; 116(1):27-33. PubMed ID: 14715304 [TBL] [Abstract][Full Text] [Related]
3. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Lee JC; Shih YF; Hsu SP; Chang TY; Chen LH; Hsu JT Anal Biochem; 2003 May; 316(2):162-70. PubMed ID: 12711336 [TBL] [Abstract][Full Text] [Related]
4. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069 [TBL] [Abstract][Full Text] [Related]
5. Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. Pan KL; Lee JC; Sung HW; Chang TY; Hsu JT Antimicrob Agents Chemother; 2009 Nov; 53(11):4825-34. PubMed ID: 19721068 [TBL] [Abstract][Full Text] [Related]
6. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease. McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594 [No Abstract] [Full Text] [Related]
7. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. Tsantrizos YS Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268 [TBL] [Abstract][Full Text] [Related]
8. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity. Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887 [TBL] [Abstract][Full Text] [Related]
9. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
10. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors. Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109 [TBL] [Abstract][Full Text] [Related]
12. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro. Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947 [TBL] [Abstract][Full Text] [Related]
13. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Sudo K; Inoue H; Shimizu Y; Yamaji K; Konno K; Shigeta S; Kaneko T; Yokota T; Shimotohno K Antiviral Res; 1996 Aug; 32(1):9-18. PubMed ID: 8863991 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116 [TBL] [Abstract][Full Text] [Related]
17. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247 [TBL] [Abstract][Full Text] [Related]
18. Reporter substrates for assessing the activity of the hepatitis C virus NS3-4A serine protease in living cells. Pacini L; Bartholomew L; Vitelli A; Migliaccio G Anal Biochem; 2004 Aug; 331(1):46-59. PubMed ID: 15245996 [TBL] [Abstract][Full Text] [Related]